comparemela.com

Latest Breaking News On - Casma therapeutics - Page 1 : comparemela.com

We need more data to help guide the care of patients with cancer who develop kidney related problems

Healthcare staff caring for patients with cancer must have access to high quality and generalizable data regarding the toxicities and repercussions of cancer treatments Onconephrology, the intersection between oncology and nephrology, is a rapidly evolving field that has gained considerable interest over the past 15 years. Cancer treatments are often highly effective at targeting cancer cells but can lead to unexpected side effects, including acute kidney injury, hypertension, and electrolyte abnormalities. These kidney related toxicities can lead to temporary or permanent discontinuation of potentially lifesaving cancer treatments. Additionally, patients with cancer are living longer and could develop chronic kidney disease after bouts of acute kidney injury, thereby jeopardizing their eligibility for future treatments, in addition to placing them at increased risk of cardiovascular disease and death.1 It is therefore essential that nephrologists, oncologists, and other providers car

FogPharma s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs

FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.